Collagen in hepatocellular carcinoma: A novel biomarker and therapeutic target
- PMID: 38967581
- PMCID: PMC11227359
- DOI: 10.1097/HC9.0000000000000489
Collagen in hepatocellular carcinoma: A novel biomarker and therapeutic target
Abstract
HCC is globally recognized as a major health threat. Despite significant progress in the development of treatment strategies for liver cancer, recurrence, metastasis, and drug resistance remain key factors leading to a poor prognosis for the majority of liver cancer patients. Thus, there is an urgent need to develop effective biomarkers and therapeutic targets for HCC. Collagen, the most abundant and diverse protein in the tumor microenvironment, is highly expressed in various solid tumors and plays a crucial role in the initiation and progression of tumors. Recent studies have shown that abnormal expression of collagen in the tumor microenvironment is closely related to the occurrence, development, invasion, metastasis, drug resistance, and treatment of liver cancer, making it a potential therapeutic target and a possible diagnostic and prognostic biomarker for HCC. This article provides a comprehensive review of the structure, classification, and origin of collagen, as well as its role in the progression and treatment of HCC and its potential clinical value, offering new insights into the diagnosis, treatment, and prognosis assessment of liver cancer.
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases.
Conflict of interest statement
The authors have no conflicts to report.
Figures


Similar articles
-
Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.Biomed Pharmacother. 2019 Jun;114:108864. doi: 10.1016/j.biopha.2019.108864. Epub 2019 Apr 10. Biomed Pharmacother. 2019. PMID: 30981107
-
HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment.J Exp Clin Cancer Res. 2017 Apr 27;36(1):60. doi: 10.1186/s13046-017-0533-1. J Exp Clin Cancer Res. 2017. PMID: 28449718 Free PMC article.
-
HMGB2 drives tumor progression and shapes the immunosuppressive microenvironment in hepatocellular carcinoma: insights from multi-omics analysis.Front Immunol. 2024 Aug 23;15:1415435. doi: 10.3389/fimmu.2024.1415435. eCollection 2024. Front Immunol. 2024. PMID: 39247201 Free PMC article.
-
Extracellular vesicles in the HCC microenvironment: Implications for therapy and biomarkers.Pharmacol Res. 2024 Nov;209:107419. doi: 10.1016/j.phrs.2024.107419. Epub 2024 Sep 14. Pharmacol Res. 2024. PMID: 39284428 Review.
-
Role of the microenvironment in hepatocellular carcinoma development and progression.Cancer Treat Rev. 2012 May;38(3):218-25. doi: 10.1016/j.ctrv.2011.06.010. Epub 2011 Jul 16. Cancer Treat Rev. 2012. PMID: 21763074 Review.
Cited by
-
Exploring SSR1 as a novel diagnostic and prognostic biomarker in hepatocellular carcinoma, and its relationship with immune infiltration.Transl Cancer Res. 2024 Oct 31;13(10):5278-5299. doi: 10.21037/tcr-24-277. Epub 2024 Oct 29. Transl Cancer Res. 2024. PMID: 39525035 Free PMC article.
-
Visualizing the Tumor Microenvironment: Molecular Imaging Probes Target Extracellular Matrix, Vascular Networks, and Immunosuppressive Cells.Pharmaceuticals (Basel). 2024 Dec 10;17(12):1663. doi: 10.3390/ph17121663. Pharmaceuticals (Basel). 2024. PMID: 39770505 Free PMC article. Review.
-
New insights into biomarkers and risk stratification to predict hepatocellular cancer.Mol Med. 2025 Apr 23;31(1):152. doi: 10.1186/s10020-025-01194-6. Mol Med. 2025. PMID: 40269686 Free PMC article. Review.
-
Extracellular matrix: unlocking new avenues in cancer treatment.Biomark Res. 2025 May 27;13(1):78. doi: 10.1186/s40364-025-00757-3. Biomark Res. 2025. PMID: 40426238 Free PMC article. Review.
References
-
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. . Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. - PubMed
-
- Toh MR, Wong EYT, Wong SH, Ng AWT, Loo LH, Chow PKH, et al. . Global epidemiology and genetics of hepatocellular carcinoma. Gastroenterology. 2023;164:766–82. - PubMed
-
- Brown ZJ, Tsilimigras DI, Ruff SM, Mohseni A, Kamel IR, Cloyd JM, et al. . Management of hepatocellular carcinoma: a review. JAMA Surg. 2023;158:410–20. - PubMed
-
- Yang C, Zhang H, Zhang L, Zhu AX, Bernards R, Qin W, et al. . Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2023;20:203–22. - PubMed
-
- European Association For The Study Of The Liver,European Organisation For Research And Treatment Of Cancer EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol. 2012;56:908–43. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical